二甲双胍降低低密度脂蛋白胆固醇的作用在长期治疗中得以维持。
The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy.
作者信息
Rains S G, Wilson G A, Richmond W, Elkeles R S
机构信息
Department of Endocrinology, St Mary's Hospital, London.
出版信息
J R Soc Med. 1989 Feb;82(2):93-4. doi: 10.1177/014107688908200213.
Abstract
Changes in serum lipoproteins were studied in 14 non-insulin dependent diabetics on long-term metformin therapy, after 6 weeks' placebo, and again 6 weeks after restarting active drug therapy. Withdrawal of metformin resulted in a rise of fasting blood glucose, HbA1, serum total and low density lipoprotein (LDL) cholesterol. Restarting the drug reversed these changes. Multivariate analysis showed that serum total and LDL cholesterol varied with treatment but not with glycaemic control. Metformin can lower serum total and LDL cholesterol in non-insulin dependent diabetics and this effect is maintained long term.
摘要
对14名接受长期二甲双胍治疗的非胰岛素依赖型糖尿病患者进行了血清脂蛋白变化的研究，在服用6周安慰剂后，以及重新开始活性药物治疗6周后再次进行研究。停用二甲双胍导致空腹血糖、糖化血红蛋白、血清总胆固醇和低密度脂蛋白（LDL）胆固醇升高。重新开始用药逆转了这些变化。多变量分析表明，血清总胆固醇和LDL胆固醇随治疗而变化，但与血糖控制无关。二甲双胍可降低非胰岛素依赖型糖尿病患者的血清总胆固醇和LDL胆固醇，且这种作用可长期维持。
相似文献
1
The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy.二甲双胍降低低密度脂蛋白胆固醇的作用在长期治疗中得以维持。
J R Soc Med. 1989 Feb;82(2):93-4. doi: 10.1177/014107688908200213.
2
The effects of oral hypoglycaemic drugs on serum lipids and lipoproteins in non-insulin-dependent diabetes (NIDDM).口服降糖药对非胰岛素依赖型糖尿病（NIDDM）患者血脂和脂蛋白的影响。
Diabete Metab. 1991 May;17(1 Pt 2):197-200.
3
The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes.格列本脲和二甲双胍对2型糖尿病患者血清脂蛋白的影响。
Diabet Med. 1988 Oct;5(7):653-8. doi: 10.1111/j.1464-5491.1988.tb01074.x.
4
Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients.瓜尔胶与二甲双胍对肥胖2型糖尿病患者空腹血糖及血脂影响的安慰剂对照试验
Diabet Med. 1990 Mar-Apr;7(3):242-5. doi: 10.1111/j.1464-5491.1990.tb01378.x.
5
Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.二甲双胍与餐时胰岛素促分泌剂瑞格列奈对非肥胖2型糖尿病患者空腹及餐后血糖和血脂反应的影响
Eur J Endocrinol. 2008 Jan;158(1):35-46. doi: 10.1530/EJE-07-0500.
6
The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.二甲双胍对2型糖尿病患者血压、血浆胆固醇和甘油三酯的影响：一项系统评价
J Intern Med. 2004 Jul;256(1):1-14. doi: 10.1111/j.1365-2796.2004.01328.x.
7
Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients.在胰岛素治疗的肥胖2型糖尿病患者中加用二甲双胍后的长期血糖改善情况。
Diabetes Obes Metab. 2001 Dec;3(6):428-34. doi: 10.1046/j.1463-1326.2001.00160.x.
8
Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.在2型糖尿病治疗中，吡格列酮与格列齐特加二甲双胍相比以及吡格列酮与磺脲类加二甲双胍相比，对脂质和脂蛋白的长期影响。
Diabetologia. 2005 Dec;48(12):2477-81. doi: 10.1007/s00125-005-0034-1. Epub 2005 Nov 10.
9
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.盐酸吡格列酮联合二甲双胍治疗2型糖尿病：一项随机、安慰剂对照研究。吡格列酮027研究组。
Clin Ther. 2000 Dec;22(12):1395-409. doi: 10.1016/s0149-2918(00)83039-8.
10
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.瑞格列奈：对其在2型糖尿病治疗中应用的药物经济学综述
Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005.
引用本文的文献
1
NF-kappa B signaling pathway is associated with metformin resistance in type 2 diabetes patients.核因子κB信号通路与2型糖尿病患者的二甲双胍耐药有关。
J Diabetes Metab Disord. 2024 Jul 6;23(2):2021-2030. doi: 10.1007/s40200-024-01458-8. eCollection 2024 Dec.
2
Cellular and Molecular Mechanisms of Metformin Action.二甲双胍作用的细胞和分子机制。
Endocr Rev. 2021 Jan 28;42(1):77-96. doi: 10.1210/endrev/bnaa023.
3
Insulin resistance: Is it time for primary prevention?胰岛素抵抗：是时候进行一级预防了吗？
World J Cardiol. 2012 Jan 26;4(1):1-7. doi: 10.4330/wjc.v4.i1.1.
4
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.2型糖尿病患者使用二甲双胍时发生致命性和非致命性乳酸性酸中毒的风险。
Cochrane Database Syst Rev. 2010 Apr 14;2010(4):CD002967. doi: 10.1002/14651858.CD002967.pub4.
5
Management of dyslipidemia in people with type 2 diabetes mellitus.2 型糖尿病患者血脂异常的管理。
Rev Endocr Metab Disord. 2010 Mar;11(1):41-51. doi: 10.1007/s11154-010-9132-6.
6
Metabolic syndrome in the elderly.老年人的代谢综合征
Curr Diab Rep. 2006 Feb;6(1):64-71. doi: 10.1007/s11892-006-0054-3.
7
A risk-benefit assessment of metformin in type 2 diabetes mellitus.二甲双胍用于2型糖尿病的风险效益评估。
Drug Saf. 1999 Jun;20(6):489-503. doi: 10.2165/00002018-199920060-00003.
8
Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.二甲双胍。其药理特性及在非胰岛素依赖型糖尿病治疗中的应用综述。
Drugs. 1995 May;49(5):721-49. doi: 10.2165/00003495-199549050-00007.
9
Treatment of diabetes: the effect on serum lipids and lipoproteins.糖尿病的治疗：对血清脂质和脂蛋白的影响。
Postgrad Med J. 1991 Oct;67(792):931-7. doi: 10.1136/pgmj.67.792.931.
10
Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles.
Eur J Clin Pharmacol. 1991;41(3):263-5. doi: 10.1007/BF00315441.
本文引用的文献
1
Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol.用于定量高密度脂蛋白胆固醇的硫酸葡聚糖-Mg2+沉淀法。
Clin Chem. 1982 Jun;28(6):1379-88.
2
The lipoproteins: predictors, protectors, and pathogens.脂蛋白：预测因子、保护因子与病原体
Br Med J (Clin Res Ed). 1983 Oct 22;287(6400):1161-4. doi: 10.1136/bmj.287.6400.1161.
3
4
Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus.2型（非胰岛素依赖型）糖尿病的死亡率与生存率
Diabetologia. 1987 Mar;30(3):123-31. doi: 10.1007/BF00274216.
5
Serum lipids, lipoproteins and macrovascular disease in non-insulin-dependent diabetics: a possible new approach to prevention.
Diabet Med. 1988 Mar;5(2):166-71. doi: 10.1111/j.1464-5491.1988.tb00965.x.
Zotero 插件